CRIM-negative infantile Pompe disease: 42-month treatment outcome

Journal of Inherited Metabolic Disease

Volumn 33, Issue 6, 2010, Pages 751-757

  Rohrbach, Marianne ^a   Klein, Andrea ^a   Köhli Wiesner, Alice ^a   Veraguth, Dorothe ^a   Scheer, Ianina ^a   Balmer, Christian ^a   Lauener, Roger ^a   Baumgartner, Matthias R ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; OMALIZUMAB; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E ANTIBODY;

ALLERGIC REACTION; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR EFFECT; CASE REPORT; CHILD; CHILD DEATH; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FEMALE; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 2; HEARING TEST; HUMAN; INFANT DISEASE; MUSCLE WEAKNESS; NEUROIMAGING; ONSET AGE; PATIENT MONITORING; PRESCHOOL CHILD; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; FOLLOW UP; IMMUNOLOGY; INFANT; TIME;

ALPHA-GLUCOSIDASES; ANTIBODIES, ANTI-IDIOTYPIC; CHILD, PRESCHOOL; CROSS REACTIONS; ENZYME REPLACEMENT THERAPY; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952551617     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9209-0     Document Type: Article

References (26)

1. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, SmithW, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA 3rd, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3:132-138
2. Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ (2010) Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 42:455-458
3. Chen CP, Lin SP, Tzen CY, Tsai FJ, HwuWL,WangW(2004) Detection of a homozygous D645E mutation of the acid alpha-glucosidase gene and glycogen deposition in tissues in a second-trimester fetus with infantile glycogen storage disease type II. Prenat Diagn 24:231-232
4. Chien YH, Lee NC, Peng SF, Hwu WL (2006) Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res 60:349-352
5. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, Chen CA,Wu MH, Huang PH, Tsai FJ, Chen YT, HwuWL (2008) Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 122:e39-e45
6. Crome L, Cumings JN, Duckett S (1963) Neuropathological and neurochemical aspects of generalized glycogen storage disease. J Neurol Neurosurg Psychiatry 26:422-430
7. Engel AG, Gomez MR, Seybold ME, Lambert EH (1973) The spectrum and diagnosis of acid maltase deficiency. Neurology 23:95-106
8. Gambetti P, DiMauro S, Baker L (1971) Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30:412-430
9. Hirschhorn R, Reuser AJJ (2001) Glycogen storage disease II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS et al (eds) The metabolic and molecular bases of inherited disease, 8th edn. Mc Graw-Hill, New York 2001:3380-420
10. Kamphoven JH, de Ruiter MM, Winkel LP, Van den Hout HM, Bijman J, De Zeeuw CI, Hoeve HL, Van Zanten BA, Van der Ploeg AT, Reuser AJ (2004) Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis 16:14-20 (Pubitemid 38569791)
11. Kishnani PS, Howell RR (2004) Pompe disease in infants and children. J Pediatr 144:S35-S43 (Pubitemid 38591273)
12. Kishnani PS,HwuWL,MandelH, NicolinoM, Yong F, CorzoD (2006a) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-676
13. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S, Davison M, Corzo D, Chen YT (2006b) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89-97 (Pubitemid 44081924)
14. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109
15. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26-33
16. Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Gorlinger K, Wallot M, Richards S, Voit T (2005) Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15:24-31 (Pubitemid 41556629)
17. Lee CC, Chen CY, Chou TY, Chen FH, Lee CC, Zimmerman RA (1996) Cerebral MR manifestations of Pompe disease in an infant. AJNR Am J Neuroradiol 17:321-322
18. Mancall EL, Aponte GE, Berry RG (1965) Pompe's disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 24:85-96
19. Martin JJ, de Barsy T, van Hoof F, Palladini G (1973) Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol 23:229-244
20. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 360:194-195
21. Muller C, Jones H, O'grady G, Suarez H, Heller J, Kishnani P (2009) Language and speech function in children with infanitle Pompe disease. J Pediatr Neurol 7:147-156
22. Sakurai I, Tosaka A, Mori Y, Imura S, Aoki K (1974) Glycogenosis type II (Pompe). The fourth autopsy case in Japan. Acta Pathol Jpn 24:829-846
23. Sidman RL, Taksir T, Fidler J, Zhao M, Dodge JC, Passini MA, Raben N, Thurberg BL, Cheng SH, Shihabuddin LS (2008) Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol 67:803-818
24. Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT (2001) Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 24:266-274 (Pubitemid 32479420)
25. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, Van der Ploeg AT (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448-e457
26. Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, Cupler E, Deschauer M, Fumic K, Jackson M, Kishnani P, Lacerda L, Ledvinova J, Lugowska A, Lukacs Z, Maire I, Mandel H, Mengel E, Muller-Felber W, Piraud M, Reuser A, Rupar T, Sinigerska I, Szlago M, Verheijen F, van Diggelen OP, Wuyts B, Zakharova E, Keutzer J (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93:275-281